摘要
目的:伴随着对抑郁发病机制的解释,抗抑郁的新药不断问世,本文着重介绍选择性5-羟色胺再摄取抑制剂的进展、代谢机制和临床安全应用等方面。方法:采用国内、外文献综述方法。结果及结论:作为抗抑郁药中的一支奇葩,选择性5-羟色胺再摄取抑制剂进展迅猛,对5-HT受体有高度的选择性,标志一个新里程的开始,从而在解除抑郁症上展现了良好的治疗前景。因此,其合理和安全应用尤为重要。
OBJECTIVE： With understading of mechanism of depressant, new anti-depressant drugs have been found constantly to summarize the aspect of clinical safety application and metabolism progress on selective serotonin reuptake inhibitor. METHODS ：To collecte medical literatures in recent years at home and abroad. RESULTS ＆ CONCLUSION：It has become the exotic flowes for anti - depressant drugs, advance in selective serotonin reuptake inhibitor has been swiftly in recent years,it has higher selectivity to 5 - HT receptor, this indicates a new start of course of development, so selective serotonin reuptake inhibitor（SSRI） plays an important roles in treatment of depressant, therefore, rational usege of oral antidiabetid drugs appears more important.
出处
《中国医院用药评价与分析》
2008年第4期253-257,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
抑郁症
安全评价
选择性5-羟色胺再摄取抑制剂
单胺氧化酶抑制剂
三环类抑郁药
Depressant
Safety evaluation
Selective serotonin reuptake inhibitor（SSRI）
Monoamine oxidase inhibitor （MAOI）
Tricyclic antidepressants （ TCAs ）
